TIANYU PHARM

TIANYU PHARM was founded in 2003, with its headquarters located in Taizhou, Zhejiang. It has a registered capital of over 180 million yuan and owns six wholly-owned subsidiaries, with more than 3,800 employees currently. TIANYU PHARM is a joint-stock pharmaceutical enterprise specializing in the research and development, manufacturing, and sales of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. It was successfully listed on the Shenzhen Stock Exchange on September 19, 2017 (Stock Code: 300702). The company is a national high-tech enterprise, a pilot innovative enterprise in Zhejiang Province, and a patent demonstration enterprise in Zhejiang Province. It has established a provincial-level corporate research institute, a provincial-level R&D center for high-tech enterprises, a provincial-level innovation platform, a provincial-level enterprise technology center, and a provincial-level post-doctoral research workstation. The company's main products cover APIs and intermediates for antihypertensive, antidiabetic, antithrombotic, and anti-asthma drugs. As one of the major global manufacturers of cardiovascular APIs, its products are sold well in both domestic and international markets.